Changes are arising in the prescription pattern for metastatic urothelial cancer due to the emergence of new treatment options.

The reimbursement of Bavencio (avelumab) as a first-line maintenance therapy, increased treatment options for the patients. The drug was first granted reimbursement only as a second-line treatment.

As demand for maintenance therapy has been high in the field, experts believe the prescription pattern will also change rapidly with Bavencio's reimbursement.

#
Urothelial carcinoma begins in the urothelial cells and is the most common type that accounts for 90% of all bladder cancer diagnoses.

Platinum-based chemotherapy, which ha